Corvus Pharmaceuticals (CRVS) Long-Term Deferred Tax (2016 - 2022)
Corvus Pharmaceuticals (CRVS) recorded quarterly Long-Term Deferred Tax of $77.0 million in Q4 2022, up 37.06% quarter-over-quarter from $56.1 million in Q4 2020.
Corvus Pharmaceuticals (CRVS) Long-Term Deferred Tax (2016 - 2022) Analysis & Trends
Corvus Pharmaceuticals' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $77.0 million for Q4 2022.
- In Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $77.0 million; the TTM figure through Dec 2022 stood at $77.0 million (changed N/A YoY), while the FY2022 annual figure was $77.0 million, changed N/A from the prior year.
- Long-Term Deferred Tax was $77.0 million for Q4 2022 at Corvus Pharmaceuticals, up from $56.1 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $77.0 million in Q4 2022 to a low of $56.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 76.95 Mn |
| Dec 31, 2020 | 56.14 Mn |
| Dec 31, 2017 | 21.89 Mn |
| Dec 31, 2016 | 12.79 Mn |